UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) **November 17, 2017**

REPRO MED SYSTEMS, INC.
(Exact name of registrant as specified in its charter)

New York	**0-12305**	**13-3044880**
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

24 Carpenter Road, Chester, New York	**10918**
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code **(845) 469-2042**

not applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company [_]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [_]

ITEM 5.02. DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.

Departure of Executive Officer

Eric Bauer, the Chief Operating Officer of Repro Med Systems, Inc. (the "Company"), has announced his resignation as an officer and employee of the Company effective November 17, 2017. The terms of Mr. Bauer's separation from the Company have not yet been determined. Mr. Bauer has agreed to assist the Company with an orderly transition.

ITEM 8.01. OTHER INFORMATION.

On November 22, 2017, the Company announced the closing of the FDA Warning Letter and certain organizational changes as a result of a comprehensive strategic review undertaken by the Board of Directors.

As part of the strategic review, the Board of Directors, encouraged by CEO and Chairman of the Board Andrew Sealfon, has initiated a search to find a qualified successor for Mr. Sealfon as CEO as soon as practicable. Mr. Sealfon continues to serve as CEO until such successor has been appointed, and Mr. Sealfon is anticipated to thereafter remain at the Company until his retirement.

A copy of the Company's press release is furnished as Exhibit 99.1 to this report.

Forward-looking Statements

The press release and this report contain forward-looking statements under the Private Securities Litigation Reform Act of 1995 including but not limited to those relating to Mr. Bauer's transition assistance. Such forward-looking statements are based on current expectations, management's beliefs and certain assumptions made by the Company's management. Actual results may differ materially.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits.

Exhibit No.	Description
99.1	Press release dated November 22, 2017

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

REPRO MED SYSTEMS, INC.
(Registrant)

Date: November 22, 2017

By: /s/ Andrew I. Sealfon
Andrew I. Sealfon
President and Chief Executive Officer

Exhibit 99.1

RMS Medical Products Announces New FDA Clearance, Warning Letter Closed, and Organizational Changes

- ***Resolution of FDA Warning Letter***
- ***Thanks to Eric Bauer for his service as Chief Operating Officer***
- ***CEO search process initiated***
- ***BOD improvements***

CHESTER, NY / November 22, 2017 / Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) today announced FDA developments and organizational changes.

The FDA has officially notified RMS that the Warning Letter issued on February 26, 2016 has been closed. This was mainly as a result of a comprehensive "Integrated Catch-Up Freedom Syringe Driver System" 510(k) K162613 which was cleared on September 1, 2017 and which not only confirmed the science behind the RMS technology but also the general and specific uses for subcutaneous (SQ) medications such as immunoglobulins and intravenous (IV) medications including antibiotics. Andy Sealfon, CEO of RMS stated, "We are thrilled and excited that FDA has recognized the leading edge concept of a constant pressure infusion system which must include everything in the fluid path to determine the performance consistent with the FDA's definition of Infusion Pump." The final chapter of closing the Warning Letter confirms that FDA has found RMS to have adequately addressed all the concerns raised in the Warning Letter. This effort was conducted under the outstanding leadership of our Chief Medical Officer, Dr. Fred Ma."

Additionally, as a result of a comprehensive strategic review undertaken by the Board of Directors, the Company is announcing certain organizational changes.

Eric Bauer has resigned from his position of Chief Operating Officer effective November 17, 2017 to pursue other opportunities, and has agreed to assist RMS with an orderly transition.

As part of the strategic review, the Board of Directors, encouraged by the CEO and Chairman of the Board Andrew Sealfon, has initiated a search to find a qualified successor for Mr. Sealfon as CEO as soon as practicable. Mr. Sealfon continues to serve as CEO until such successor has been appointed, and Mr. Sealfon is anticipated to remain at the Company until his retirement.

Finally, in an effort to prepare the Company for anticipated growth, the Board of Directors has committed to strengthening its membership and governance in coming months.

About RMS Medical Products

The Company manufactures medical products used for infusions and suctioning. The Infusion product portfolio currently includes the FREEDOM60$^{(R)}$ and our latest FreedomEdge™ Syringe Infusion Pumps, RMS Precision Flow Rate Tubing$^{(TM)}$ and RMS HIgH-Flo $^{(TM)}$ Subcutaneous Safety Needle Sets. These devices are used for infusions administered in professional healthcare settings as well as at home. The Company's RES-Q-VAC line of medical suctioning products is used by emergency medical service providers in addition to a variety of other healthcare providers.

The Company’s website may be visited at www.rmsmedicalproducts.com.

This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms “anticipated”, “believes”, “belief”, “expects”, “intends”, “anticipates”, “will”, or “plans” to be uncertain and forward looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s reports and registration statements filed with the Securities and Exchange Commission.

For more information please call:
Mike King
702 650 3000
Princeton Research
SOURCE: RMS Medical Products